“ Compound 14 ” (Shionogi Pharmaceuticals) is a nicotinamide N -methyltransferase (NNMT) inhibitor. For some “difficult to drug” targets such as protein-protein interactions , peptides are attractive therapeutic modalities due to their high binding specificity and synthetic accessibility. Macrocyclization of peptides may help improve [...]
4 minute read
Aug. 26, 2022
Compound 14: a Nicotinamide N-Methyltransferase (NNMT) Inhibitor
compound 14
elective NNMT inhibitor 100-times higher inhibitory activity than original peptide peptide library screening, de novo design and SBDD J. Med. Chem., July 29, 2022 Shionogi Pharmaceutical Research Center, Toyonaka, JP